SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is generating strong community buzz as its AI-powered ecosystem expands with new exchange listings and cross-chain integrations, leading many to anticipate significant price milestones and further utility growth.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl (KD) is experiencing an intense sell-off and community debate following the abrupt departures of its CFO and general counsel amid an ongoing accounting review, delayed regulatory filings, and reduced financial guidance. While many see the over 50% plunge as an extreme overreaction and a potential buying opportunity, others express deep concern over financial irregularities, referencing a past short report, and caution against further downside.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group is soaring after pre-announcing preliminary Q3 revenue well above expectations and reiterating robust fiscal year growth, fueling strong community belief that the AI data center infrastructure play was significantly undervalued amid massive hyperscaler capital expenditure. Traders are actively discussing the stock's sharp rebound and its potential for continued upside as a key beneficiary of the ongoing AI buildout.

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Satellos Bioscience Inc

Satellos Bioscience (MSLE) is trending following its recent NASDAQ listing and a significant $50 million financing, sparking intense debate around its novel Duchenne Muscular Dystrophy drug, SAT-3247. The community is split between those hailing its "revolutionary" muscle regeneration potential and acquisition prospects, and skeptics citing its early-stage data and concerns over dilution.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies Inc

Rocket Companies is seeing significant conversation after its CEO signaled multi-year highs in mortgage loan production and gain-on-sale performance, leading to community debate on whether its integrated platform can overcome broader housing market headwinds amidst ongoing institutional accumulation.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is trending as its highly dedicated community champions a "permissionless brand" model, consistently launching real-world products like KENDU SPICE, fostering strong conviction and active accumulation even amidst broader market downturns. This unique approach to building real value differentiates it as a long-term play.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is a top trending stock as investors keenly await its earnings report tomorrow, with significant community speculation around a potential beat and strong guidance. Many perceive the cloud observability leader as an undervalued AI beneficiary after recent sector-wide pressures, driving discussions of a major buying opportunity.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is actively discussed as the community awaits crucial R2 SUV details and earnings, with its CEO emphasizing the R2's cost-efficient design and potential to significantly boost profitability, though investor sentiment remains divided on its market impact and the company's cash burn amid EV sector competition.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending following the FDA's issuance of a Complete Response Letter for its Hunter syndrome gene therapy, RGX-121, citing concerns with trial design and the appropriateness of its surrogate endpoint. The community is actively debating the broader implications for gene therapies, RGNX's financial outlook, and potential impacts on its Duchenne and AbbVie-partnered programs.

Syntec Optics Holdings, Inc. engages in the design and manufacture of optics and photonics enabled products. The company was founded in 1981 and is headquartered in Rochester, NY.

Syntec Optics Holdings Inc. - Ordinary Shares - Class A

Syntec Optics Holdings Inc

Syntec Optics (OPTX) is gaining traction from new ballistic optics orders for U.S. military augmented reality systems and increasing demand for its space and AI data center optics. The community is actively debating its low float and significant growth potential from defense and AI tailwinds against concerns over its current valuation and cash position.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Century Therapeutics, Inc. (NASDAQ:IPSC) Receives Average Rating of "Moderate Buy" from Analysts

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the company, MarketBeat...

Century Therapeutics (NASDAQ:IPSC) Lowered to "Sell" Rating by Wall Street Zen

Wall Street Zen cut Century Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday...

Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Grows By 148.0%

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) was the recipient of a large growth in short interest in January. As of January 15th, there was short interest totaling 807,117 shares, a...

Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know

Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Rises By 32.1%

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling...

FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug

Alkermes wins FDA Breakthrough Therapy status for alixorexton in NT1 after Vibrance-1 data shows improvement in wakefulness. 

Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Century Therapeutics (IPSC) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Century Therapeutics (NASDAQ:IPSC) Insider Buys 58,060 Shares

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) insider Chad Cowan bought 58,060 shares of the business's stock in a transaction that occurred on Monday, December 22nd. The shares were...

Chad Cowan Buys 58,060 Shares of Century Therapeutics (NASDAQ:IPSC) Stock

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) insider Chad Cowan purchased 58,060 shares of the stock in a transaction dated Monday, December 22nd. The shares were purchased at an...

Century Therapeutics, Inc. (NASDAQ:IPSC) Sees Significant Decrease in Short Interest

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) was the recipient of a large drop in short interest during the month of December. As of December 15th, there was short interest totaling...

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It focuses on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.

Century Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Current Price	$1.95
Prev Close	$1.70
Open	$1.71
Dividend Yield	0.00%
50-Day Moving Average	$1.31
Beta	1.56
Avg. Volume	2.97M
PE Ratio	-5.47

52-Week High	$2.71
52-Week Low	$0.3418
Market Capitalization	$148.59M
EPS (Annual)	-$1.61
Price to Book	0.83
Revenue Per Employee	$43,926.67
Enterprise Value/EBITDA	N/A

IPSC
Century Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IPSC News

IPSCCentury Therapeutics Inc